A randomized phase II open-label study of two different dose levels of PX-12 in patients with advanced carcinoma of the pancreas whose tumors have progressed on gemcitabine or on a gemcitabine-containing combination

Trial Profile

A randomized phase II open-label study of two different dose levels of PX-12 in patients with advanced carcinoma of the pancreas whose tumors have progressed on gemcitabine or on a gemcitabine-containing combination

Discontinued
Phase of Trial: Phase II

Latest Information Update: 12 Sep 2016

At a glance

  • Drugs PX 12 (Primary)
  • Indications Pancreatic cancer
  • Focus Biomarker; Pharmacodynamics; Therapeutic Use
  • Most Recent Events

    • 30 May 2009 Status changed from active, no longer recruiting to discontinued. Enrolment in this trial was terminated in early 2009. The Company intends to seek a partner for further development of this drug candidate. Reported in an Oncothyreon media release.
    • 24 Mar 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 22 Jan 2009 Planned end date is now 1 Jul 2009 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top